EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Osteonecrosis of the femoral head: a rare complication of combination therapy with bevacizumab and atezolizumab in a patient with non-small cell lung cancer

Tatyana D. Barbolina, Svetlana G. Bagrova, Aleksandra V. Fedorova

Journal of Clinical Practice · 08.04.2026 · 17 (2) · 157-167

DOI: 10.17816/clinpract688820 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Practice, online erschienen am 08.04.2026. Verfasst von Tatyana D. Barbolina und 2 weiteren Autor:innen. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anti-angiogenic therapy is used in the treatment of many solid malignant neoplasms, both alone and in combination with immunotherapy, targeted therapy, and chemotherapy. Complications of drug therapy for malignant neoplasms may necessitate the permanent discontinuation of antitumor therapy, resulting in disability. These complications include bone disorders. Osteonecrosis of the jaw is most commonly associated with bone-modifying agents (bisphosphonates); however, it is extremely rare with other drugs. Necrosis of the femur is even less common. CLINICAL CASE DESCRIPTION: This article presents a clinical case of bilateral avascular necrosis of the femoral head in a patient with disseminated non-small cell lung cancer who was receiving long-term combination immunotherapy and targeted therapy. CONCLUSION: Avascular necrosis of the femoral head is a major concern, considering the expanding range of drug therapies for various malignant neoplasms and novel combination therapy options. The lack of a clear algorithm for managing patients with this serious complication of antitumor drug therapy highlights the relevance of this issue.

Zitieren

APA

Barbolina, T. D., Bagrova, S. G., & Fedorova, A. V. (2026). Osteonecrosis of the femoral head: a rare complication of combination therapy with bevacizumab and atezolizumab in a patient with non-small cell lung cancer. Journal of Clinical Practice, 17(2), 157-167. https://doi.org/10.17816/clinpract688820

Vancouver

Barbolina TD, Bagrova SG, Fedorova AV. Osteonecrosis of the femoral head: a rare complication of combination therapy with bevacizumab and atezolizumab in a patient with non-small cell lung cancer. Journal of Clinical Practice. 2026;17(2):157-167. doi:10.17816/clinpract688820

BibTeX
@article{Barbolina2026,
  author = {Barbolina, Tatyana D. and Bagrova, Svetlana G. and Fedorova, Aleksandra V.},
  title = {Osteonecrosis of the femoral head: a rare complication of combination therapy with bevacizumab and atezolizumab in a patient with non-small cell lung cancer},
  journal = {Journal of Clinical Practice},
  year = {2026},
  volume = {17},
  number = {2},
  pages = {157--167},
  doi = {10.17816/clinpract688820}
}
Kostenlos starten →